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Abstract
Background: Recent trials demonstrate the acceptability and short term efficacy of primary care referral to a
commercial weight loss provider for weight management. Commissioners now need information on the optimal
duration of intervention and the longer term outcomes and cost effectiveness of such treatment to give best value
for money.
Methods/Design: This multicentre, randomised controlled trial with a parallel design will recruit 1200 overweight adults
(BMI ≥28 kg/m2) through their primary care provider. They will be randomised in a 2:5:5 allocation to: Brief Intervention,
Commercial Programme for 12 weeks, or Commercial Programme for 52 weeks. Participants will be followed up for two
years, with assessments at 0, 3, 12 and 24 months. The sequential primary research questions are whether the CP
interventions achieve significantly greater weight loss from baseline to 12 months than BI, and whether CP52 achieves
significantly greater weight loss from baseline to 12 months than CP12. The primary outcomes will be an intention to
treat analysis of between treatment differences in body weight at 12 months. Clinical effectiveness will be also be
assessed by measures of weight, fat mass, and blood pressure at each time point and biochemical risk factors at
12 months. Self-report questionnaires will collect data on psychosocial factors associated with adherence, weight-loss and
weight-loss maintenance. A within-trial and long-term cost-effectiveness analysis will be conducted from an NHS
perspective. Qualitative methods will be used to examine the participant experience.
(Continued on next page)
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Discussion: The current trial compares the clinical and cost effectiveness of referral to a commercial provider with a brief
intervention. This trial will specifically examine whether providing longer weight-loss treatment without altering content
or intensity (12 months commercial referral vs. 12 weeks) leads to greater weight loss at one year and is sustained at
2 years. It will also evaluate the relative cost-effectiveness of the three interventions. This study has direct implications for
primary care practice in the UK and will provide important information to inform the decisions of practitioners and
commissioners about service provision.
Trial Registration: Current Controlled Trials ISRCTN82857232. Date registered: 15/10/2012.
Keywords: Obesity, Weight-loss, Primary care, Adults
Background
Obesity has trebled since the 1980s and globally, excess
weight is estimated to account for 44% of diabetes, 23%
of ischemic heart disease and 7-41% of some cancers [1].
There is good evidence that intensive lifestyle interven-
tions can produce weight loss linked to clinically signifi-
cant health benefits [2], but such specialist interventions
are costly given the high prevalence of obesity. Interven-
tions delivered in primary care can also be demanding in
terms of staff resources, set up and training and partici-
pant weight loss is often less than 5% of initial weight
[3,4]. In the UK, NICE recommends consideration of
any intervention that meets best practice, including re-
ferral to commercial weight loss programmes [5]. Com-
mercial programmes are usually delivered in large
groups by lay people, and preliminary evidence suggests
they may be more affordable than interventions led by
health professionals, making weight loss initiatives avail-
able for more individuals [6,7].
A number of commercial weight loss providers currently
operate referral schemes for Public Health and the National
Health Service (NHS) in the UK, whereby commissioners
can purchase 12 week referral packages at a reduced cost,
which are provided at no cost to patients. Two randomised
controlled trials conducted by members of the current re-
search team have demonstrated the effectiveness of com-
mercial referrals. Jolly et al. compared a number of 12 week
weight loss interventions in Birmingham’s Lighten Up ser-
vice, including three commercial providers, to a control
intervention (12 vouchers to attend a leisure centre) [8].
Twelve-month weight loss was significantly greater among
participants referred to a commercial programme (Weight
Watchers; WW) than control participants [−4.35 ± 6.9 kg
vs −1.63 ± 6.0 kg; p < 0.001]. Jebb et al. [9] demonstrated
that overweight and obese adults referred to this commer-
cial programme by their primary care provider for
12 months lost twice as much weight as those who received
standard care [−5.1 ± 6.1 kg vs 2.3 ± 4.2 kg; p < 0.001].
These findings suggest that referral to a commercial
programme (CP) by a primary care provider is a clinically
effective weight loss intervention over a one year period.
However, limited data on participants who agreed to attend
further follow up suggests significant weight regain beyond
programme end [10].
The NHS currently provides 12 week referrals to com-
mercial programmes. There is conflicting evidence on
whether providing longer treatment interventions could re-
sult in greater and more sustained weight loss. In one
meta-analysis of studies providing ‘extended care’ , partici-
pants receiving extended care had, on average, 3.2 kg less
weight regain than controls over a mean follow up period
of 17.6 months [11]. The reduced weight regain in the ex-
tended care intervention in studies with 6–12 month
follow-up was at least 1.5 kg. However, in a recent review
of behavioural weight management programmes, meta-
regression of trials with longer and shorter programmes
found no benefit of longer programmes up to 1 year [12].
Indirect comparisons from Jebb et al. and Jolly et al. suggest
that 12 months CP (weight loss 5.1 kg) achieves greater loss
than 12 weeks CP (weight loss 4.4 kg, assessed at
12 months). The difference is small, but participants in Jolly
at al. were heavier and older than those in the Jebb et al.,
two factors associated with greater weight loss in an audit
of the CP’s NHS referral database [13] and an observational
analysis of the routine Lighten Up service [14]. Thus we
might anticipate the difference in weight loss after 12 or
52 weeks intervention in comparable groups to be greater
than the comparison between these two studies. Moreover,
further analysis of Jolly et al. suggests the apparent impact
of the WW intervention may have been atypically high. In
the two other commercial providers (Slimming World and
Rosemary Conley), mean weight loss at 12 months was
smaller than WW, yet a much larger comparison (n =
3000) of the three providers in the routine Lighten-Up re-
ferral service shows that mean self-reported weight loss at
1 year in those attending WW was very close to the mean
weight loss across all providers [14]. Mean 12 month weight
loss for the three CPs in Jolly et al. was 2.7 kg, giving an as-
sumed difference of 1.36 kg between this and the 52 weeks
intervention in Jebb et al. A formal RCT is needed to show
whether the greater loss in the 12 month programme is due
to the longer referral and the current trial will directly com-
pare weight loss at 12 months for participants receiving
12 weeks referral (CP12) and 52 weeks referral (CP52).
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Obesity is a chronic, relapsing condition and the sus-
tainability of weight loss achieved in short term inter-
ventions cannot be assumed. There is currently no
published data on 12 week commercial referral out-
comes beyond 12 months. In the limited data from par-
ticipants from Jebb et al., 12 months CP did lead to
greater weight loss than standard care, but this differ-
ence was small and sensitive to assumptions about miss-
ing data [10]. We will therefore follow participants up
for 24 months to examine whether any initial differences
in weight loss are sustained in the longer term.
Careful consideration has been given to the most appro-
priate control intervention. Since in many cases, obesity re-
mains untreated in primary care, a no-intervention control
may be considered to reflect standard care. However, recog-
nition of obesity by GPs as part of recruitment to the trial
and appointments for outcome measurements may consti-
tute an intervention in its own right and in a recent review
even minimal intervention ‘control’ groups lost weight [12].
Where offered, weight management interventions in pri-
mary care vary considerably. Since this is not the focus of
this trial it is important to have a standardised ‘control’
intervention. Inclusion of a brief intervention based on
written self-help materials will allow us to control for the
impact of the GP offering a weight loss intervention and
trial participation on weight loss and allow some consider-
ation of the relative contribution of engagement and
follow-up versus the nature and content of the specific
intervention provided.
For NHS commissioners, one of the most important
questions is whether an intervention offers value for money
and a rigorous evaluation of cost-effectiveness has been
built into the trial. Data on treatment costs, health-care
usage and quality of life [15] will enable us to model
whether any additional weight loss achieved through the
52 week programme is worth the additional costs. Initially
this will consider cost-effectiveness from the perspective of
the NHS, within the period of the trial (i.e. 24 months),
However, ultimately, we want to know whether the inter-
ventions are likely to lead to an increase in length and qual-
ity of life, and at what cost. It is not practical to conduct a
prospective study with lifetime follow up to establish this.
Instead we propose using a well-developed decision-
analytic model to estimate the long term impact of weight
loss on risks of chronic disease and hence quality adjusted
life years (QALYs) and cost.
Qualitative data suggests neither participants nor prac-
titioners view weight management services as a priority
in primary care and that some resist the idea that it is a
medical issue in and of itself [16]. Thus, by delivering
the intervention outside of a medical context, a CP fits
better with participants’ own view of weight manage-
ment. This study will examine participant experience in
greater depth to explore the ways in which individuals
understand and make sense of the imperative to lose
weight, and the values and tensions arising from the pri-
mary care- commercial provider relationship. It will also
examine the extent to which the weekly weigh in and
the sense of peer support are experienced to be key as-
pects of the CP and the extent to which these are felt to
facilitate weight loss.
Interventions for weight management could potentially
be improved by developing a greater understanding of the
psychosocial factors that explain individual variation in ad-
herence, weight loss and post-intervention weight mainten-
ance. There is a particular lack of knowledge about how
these factors change during weight loss and how they affect
weight maintenance. The current study will use validated
questionnaires to explore a number of psychosocial factors
that have either demonstrated an association with attrition,
weight loss, and maintenance of weight lost in previous
studies, or represent constructs identified as potentially
important predictors of weight loss maintenance in
recent reviews [17-19]. We will examine how baseline
differences in these factors affect weight trajectories,
how these factors change during and following a weight
loss intervention, and how changes are associated with
changes in weight.
Objectives
Primary objectives
The primary research question is whether the CP inter-
ventions achieve significantly greater weight loss from
baseline to 12 months than BI, and whether CP52
achieves significantly greater weight loss from baseline
to 12 months than CP12.
Secondary objectives
Clinical effectiveness
We will examine differences between the three inter-
ventions in weight, waist circumference, body compos-
ition, and blood pressure at 3, 12 and 24 months and
differences in biochemical measures (blood glucose,
total cholesterol, HDL cholesterol, LDL cholesterol, and
HbA1c) at 12 months. Specifically we will test the fol-
lowing hypotheses:
i) Both CP interventions achieve significantly greater
weight loss than BI from baseline to 3 months and
baseline to 24 months and CP52 produces
significantly greater weight loss than CP12 from
baseline to 24 months.
ii) Both CP interventions achieve significantly greater
improvements in waist circumference, body
composition and blood pressure than BI between
baseline and 3, 12 and 24 months.
iii) CP52 achieves significantly greater improvements in
waist circumference, body composition and blood
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pressure than CP12 between baseline and 3, 12 and
24 months.
iv) Both CP interventions achieve significantly greater
improvements in biochemical measures than BI
between baseline and 12 months, and CP52 achieves
significantly greater improvements than CP12.
Cost-effectiveness
We will examine the cost-effectiveness of each of these
interventions. The following hypotheses will be tested:
i. CP52 is more cost-effective than CP12, as assessed
by both within trial cost effectiveness and long term
cost-effectiveness analyses.
ii. Both CP12 and CP52 are more cost-effective
than BI.
Participant experience
A qualitative workstream will explore the attitudes of
participants to primary care referrals to commercial
providers for weight loss, and also their wider experi-
ences of weight management. In line with a qualitative
research methodology, the following three areas will act
as a guide for the research that will also remain sensitive
to the experiences and topics raised by participants:
i) The extent to which participants feel that they have
been referred for weight management in the NHS by
their GP, and how this relates to their experience of
participating in the programme and their attitudes
toward weight loss.
ii) The extent to which the weekly weigh in and the
sense of peer support are experienced to be key
aspects of the CP
iii)The extent to which being ‘overweight’ or ‘obese’ is
considered a medical issue by participants
Psychosocial factors
This study will also examine psychosocial factors that
are associated with completion of the intervention,
weight loss and weight loss maintenance, to enable
greater understanding of who benefits from these
interventions and to inform development of new
interventions.
Biological sampling
This study will collect blood samples in order to exam-
ine changes in markers of risk of CVD and diabetes
(fasting lipids, glucose and glycosylated haemoglobin).
DNA will be collected for subsequent analyses of how
genetic variation effects response to the interventions.
Method
Trial design
This is a multicentre, randomised controlled trial with
a parallel design. Participants will be randomised to one
of three interventions: Brief Intervention (BI), Com-
mercial Programme for 12 weeks (CP12) or Commercial
Programme for 52 weeks (CP52) in an allocation of 2:5:5
(Figure 1).
Population
Overweight and obese adults (BMI ≥ 28) in the UK,
deemed eligible for weight management intervention by
their general practitioner.
Setting
Participants will be recruited through primary care prac-
tices across England by three research centres. MRC
Human Nutrition Research is the coordinating centre.
They will recruit through local practices in Cambridgeshire
and all measurements will be conducted by trained
research staff at the research centre. The University of
Liverpool will recruit through local practices across
Merseyside and all measurements will be conducted by
trained research staff at the research centre. The University
of Oxford will recruit through practices across England
and measurements will be conducted by trained health
professionals (usually a research nurse) in the practice.
Recruitment started in October 2012 and was completed
in February 2014.
Participants
Participants will be 1200 overweight and obese adults in
England, recruited by their local primary care provider.
Inclusion criteria
The inclusion criteria are BMI ≥28 kg/m2, aged ≥18 years,
and willing and able to comply with the study procedures.
For simplicity, we will not vary the BMI criteria by ethnic
group.
Exclusion criteria
The exclusion criteria are: planned or current pregnancy in
the next two years; previous or planned bariatric surgery;
currently following a weight-loss programme (defined as a
structured, prescribed and monitored programme and not
a self-regulated diet); non-English Speaking or with Special
Communication needs that would preclude them from un-
derstanding the study materials and interventions. GP’s will
exclude patients who are inappropriate to invite into the
study, for example patients who are violent/terminally ill/
have a history of an eating disorder. GPs will also be
allowed to define any additional inclusion/exclusion criteria
to meet local practice and will be asked to provide details
on these for the reporting of the study. No further criteria
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will be imposed, thus capturing the population that would
typically be referred to these treatments. Participants re-
ceiving other weight loss treatments, e.g. Orlistat, will not
be excluded as such participants would still be eligible for
commercial referrals in standard practice, but this will be
adjusted for in the analyses. Participants will be randomised
to intervention arms, and thus those receiving additional
treatment should be evenly spread across the interventions
and these treatments will be accounted for in the cost-
effectiveness analyses.
Inclusion of same household partners
Where more than one individual from a household is
eligible and wants to enrol in the study, both members
of the household will be allocated to the same treatment
group (randomising participants at the household rather
than the individual level) but only one person per house-
hold (the first to enrol) will be enrolled as a ‘participant’
who will provide measurements for the trial and attend
follow-up visits. The ‘non-participant’ member(s) of a
household will be referred to as ‘same household part-
ner’, and will attend a ‘baseline’ visit to give consent and
to receive their intervention materials. The ‘same house-
hold partner’ will be asked for consent to obtain their
attendance and weight data from Weight Watchers (if
they are allocated to this arm) through their WW NHS
Referral Database. There is also potential for participants
to be part of a household where other members are
engaged in weight loss programmes, outside of this
study. Therefore, all participants will be asked to provide
information about weight loss activities within their
household, regardless of whether they have a partner in
the study or not.
Recruitment
GP practices will be identified and recruited by the local
Primary Care Research Network (PCRN). Practices will
be targeted that do not have an existing contract with
commercial weight loss services. In this way participants
allocated to the brief intervention will not be denied
standard care.
Based on the 10% recruitment rate from Jolly et al., we
will approach approximately 12000 eligible individuals to
recruit 1200 participants. The primary care provider will
search their electronic registers for eligible individuals
and GPs will screen out those to whom it would be in-
appropriate to send a letter (for example patients known
to have a history of eating disorders or to be terminally
Excluded  
– Planned/Current Pregnancy
– Planned/Previous Bariatric Surgery
– Unable/Unwilling to participate
Baseline Assessment and Randomisation
(N=1200) 
52wks Commercial Programme 
(N=500)
Receive vouchers for 1 year  
Weight Watchers membership
Brief Intervention 
(N=200)
Receive written information about 
weight loss strategies
Enrollment
24 month Assessment 24 month Assessment24 month Assessment
Recruitment
Allocation
Invitations sent to ~12000
Eligible individuals identified 
by primary care provider
3 month Assessment
12 month Assessment 12 month Assessment12 month Assessment
3 month Assessment 3 month Assessment
Follow-Up
1 2wks Commercial Programme 
(N=500)
Receive vouchers for 12 Weight 
Watchers sessions
Same Household Participants
Qualitative 
Interview
N~45
Figure 1 Participant flow diagram.
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ill). The letter will not mention the participant’s weight,
but offers the availability of weight management and also
will give brief details of the trial. Interested participants
will be asked to telephone (on a designated Freephone
number) or email the study co-ordinator at their local
site for further information. A member of the research
team will then describe the trial to the potential partici-
pant, undertake further screening, and, if agreeable, offer
an appointment for baseline assessment and enrolment
in the trial. This will be confirmed by letter, accompan-
ied by a participant information sheet.
We will monitor uptake of the trial by ethnic group
and by gender. GPs will be asked in their search for eli-
gible participants to report summary statistics of the
gender and ethnic composition of the eligible popula-
tion. By comparing the recruited population to the eli-
gible population we will be able to examine whether
take-up of referral differed by ethnicity or gender.
Randomisation
At the first assessment, a member of the research team
trained in taking informed consent will ensure that the
participant understands the trial and has read the par-
ticipant information sheet. They will confirm their eligi-
bility for the study and obtain written consent for their
participation in the trial. Participant details, including
baseline weight, will be entered into an online database
by a member of the research team.
The database will automatically assign participants with a
valid recorded baseline weight to one of three interventions
(BI, CP12, CP52). The randomisation sequence was gene-
rated by the trial statistician and allocates participants in a
2:5:5 allocation stratified by centre and gender, with a block
size of 12. The sequence is unknown to research staff and
participants.
Due to the nature of the intervention and the trial de-
sign, neither participants nor research staff will be
blinded to the intervention allocation.
Withdrawal
Participants are free to withdraw from the trial at any time,
without this affecting their care, by informing a member of
the research team. Participants who withdraw will not be
replaced, and data already collected will be used unless the
participant requests that it be removed.
Participants might choose not to attend the commer-
cial weight loss programme, or may stop attending ses-
sions during the trial. Participants who withdraw from
the intervention will be followed up at assessment ap-
pointments in the same way as other participants unless
they also choose to withdraw from the trial.
Three contact attempts (by different means and at dif-
ferent times) will be made for each follow up appoint-
ment. On the third attempt to schedule an appointment,
or where a participant informs us that they are unable
or unwilling to attend a follow up appointment, a self-
measured weight will be requested. These data will not
be included in the primary analyses but will provide add-
itional data that can be used for sensitivity analyses
where it is considered appropriate.
Interventions
Referral to a commercial provider
Participants who are assigned to the two commercial refer-
ral arms will receive vouchers to attend Weight Watchers
sessions and asked to attend a local meeting that is con-
venient for them. They will be asked not to mention their
participation in the trial to the group leader or other mem-
bers, to make their experience as representative as possible.
CP12: Participants allocated to the 12 week referral
will receive free vouchers to attend 12 Weight Watchers
sessions and access to their internet resources for
16 weeks. This is the package currently used in the
WW NHS Referral Scheme and currently costs the
NHS £55 + VAT.
CP52: Participants allocated to the 52 week referral
will receive free vouchers to attend 52 sessions of
Weight Watchers and access to their internet resources
for 12 months. This packages is estimated to cost the
NHS £190 + VAT.
Brief intervention
The control intervention is a standardised brief interven-
tion: recognition of the problem by the GP (letter of in-
vitation), basic written information on self-help weight
loss strategies provided by a member of the research
team at the baseline visit (British Heart Foundation
Booklet: So you want to lose weight… for good) and
weighing at follow up (coincides with outcome measure-
ments at 3, 12 and 24 months).
Adherence
Attendance at CP meetings will be monitored both
through self-report at assessment appointments and data
collected by WW at weekly meetings (which can be pro-
vided, with consent, through the WW NHS referral
database and tracked using NHS referral ID) and these
data will be controlled for in sensitivity analyses. Similar
information may be available from WW regarding web-
site usage, and this data will be combined with that col-
lected via self-report. We will also collect self-report
data on the extent to which BI participants have used
their self-help materials.
Outcomes
Clinical effectiveness outcomes
The primary outcome will be body weight (kg) at
12 months. Secondary clinical outcomes will be: body
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weight (kg) at 3 and 24 months, whether a participant
has lost ≥5% and ≥10% of initial body weight at 3, 12
and 24 months; waist circumference, body composition,
and blood pressure at 3, 12 and 24 months; blood glu-
cose, total cholesterol, HDL cholesterol, LDL cholesterol,
and HbA1c at 12 months.
Cost-effectiveness outcomes
The incremental cost-effectiveness ratio (ICER) of the inter-
vention is the main outcome of the economic evaluation
and will be expressed as incremental costs per incremental
change in weight/BMI for the within-trial evaluation.
Adverse events
This is a low risk trial with little reason to consider that
adverse events would arise as a result of following any
one of the interventions. Accordingly no formal adverse
event monitoring is planned.
Visits and measurements
Participants will attend measurement appointments at 0,
3, 12 and 24 months. Details of which measures will be
taken at which appointments are summarised in Table 1.
Clinical measurements
All clinical measurements will be made in line with stan-
dardised operating procedures by trained research staff.
Participants will be asked to remove shoes and heavy
clothing items. Height (cm) will be measured in cm
using a stadiometer. Weight and fat mass will be mea-
sured in kg using a Tanita segmental body composition
analyser. Waist circumference (cm) will be measured
using a tape measure, half way between the lowest rib
and the iliac crest. Blood pressure will be measured
using standardised methods.
Biochemical measurements
Biochemical measurements are optional for participants
and taken under separate consent. Blood samples will be
Table 1 Schedule of enrolment, interventions, and assessments
STUDY PERIOD
Enrollment Baseline visit Post allocation Close-out
TIMEPOINT -t1 0 3 months 12 months 24 months
ENROLMENT:
Eligibility screen X X
Informed consent X
Allocation X
INTERVENTIONS:
Brief Intervention X
12 weeks Commercial Programme X X
52 weeks Commercial Programme X X X
ASSESSMENTS:
Height X
Weight X X X X
Fat mass X X X X
Waist Circumference X X X X
Blood Pressure X X X X
Blood Glucose X X
Lipid Profile X X
HbA1c X X
DNA X
Demographics Questionnaire X X X X
Health Care Usage Questionnaire X X X X
EQ5D X X X X
Psychosocial Questionnaires X X X X
Intervention Usage Questionnaires X X X X
Qualitative Interviews (subset only) X
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taken by fully trained research staff in line with standar-
dised operating procedures. For assessment appoint-
ments where blood will be taken (0 and 12 months),
participants will be asked to attend in a fasted state
(no food or drink for 12 hours prior to the appointment).
At baseline and 12 months, participants will provide a
sample of whole blood for analysis of glucose, glycosy-
lated haemoglobin (HbA1c) and lipid profile. At baseline,
an additional sample of whole blood will be collected in
an EDTA tube, frozen at −80 and stored for later extrac-
tion of DNA and outside the trial protocol.
Health care usage measures
At each visit, participants will complete a Health Care
Usage Questionnaire to assess their use of Health Care
Services in the last 3 months.
Psychosocial measures
Participants will complete a series of questionnaires at
or before each assessment to assess psychosocial factors
related to weight control.
The Flexible and Rigid subscales if the Eating Inventory
[20] measure cognitive dietary restraint and distinguish
flexible and rigid dietary restraint strategies.
The Power of Food Scale (PFS) [21] measures indivi-
dual differences in hedonic hunger (hunger in the absence
of energy need).
A visual analogue scale (VAS) will be used to assess
state hunger at the time the questionnaire is completed
[22]. Sensitivity analyses can examine whether this
influences responses to questionnaires about eating
behaviour.
The Self-Report Habit Index (SRHI) [23] is a measure
of behavioural frequency, automaticity and identity,
which has also been used to measure the automaticity of
thoughts, such as body-related cognitions. In the current
study, we will use this measure to examine the extent to
which “watching what I eat” and “exercising regularly”
become automatic and are seen as part of a participant’s
identity, and the extent to which this predicts weight
loss and weight loss maintenance.
The Treatment Self-Regulation Questionnaire; Diet
Self-Regulation Questionnaire (DSRQ) and Exercise Self-
Regulation Questionnaire (ESRQ) measure the extent to
which a participant’s motivation to participate in treat-
ment, eat a healthy diet, or exercise, is autonomous (i.e.
they are motivated by personal reasons) or controlled (i.e.
they are motivated by perceived pressure from others).
The Problem Eating Behaviours Questionnaire (PEBQ)
[24] measures the extent to which particular eating
behaviours are problematic for participants.
The EQ5D [15] is a self-report measure of quality of
life, which will be used to calculated QALYs for the cost-
effectiveness analysis.
We will measure life satisfaction using the Satisfaction
with Life Questionnaire (SLQ) [25] and depression and
anxiety using the Hospital Anxiety and Depression Scale
(HADS) [26].
Qualitative data collection
A subset of participants from the Cambridge centre will
be recruited to participate in a qualitative study. Data
will be collected through semi-structured interviews
with up to 15 participants in each intervention. A
maximum-variation (heterogeneity) sampling technique
will be used to select potential interviewees based on
demographic information obtained during the telephone
screening questionnaire and through a questionnaire at
the baseline visit. At the 3 month visit selected partici-
pants (including some who have dropped out of treat-
ment but not withdrawn from follow-up) will be invited
to participate in an interview. Participants will be offered
the choice between having the interview at their home
or in a private office at the University of Cambridge.
Interviews will not be held where study procedures are
conducted, to reduce associations between the interview
and the measurement visits of the trial in order to
encourage participant’s to speak openly about their expe-
riences of the intervention to which they have been
assigned. Interviews will last approximately one hour
and will follow a general topic guide that will be piloted
with a subset.
Statistical analysis
Analysis design
There is already good evidence to suggest that CP pro-
duces significantly greater weight loss than BI and in the
event that CP is not better than BI then the comparison
of the CP arms would not be of interest. Accordingly we
will conduct a sequential analysis, which will preserve
the Type 1 error of 5% without the need for a multi-
plicity correction such as Bonferroni. The sequential
analysis will consist of the following 2 stages:
i) Test the one-sided hypothesis that weight loss in the
CP groups combined is greater than the weight loss
in the BI arm.
ii) If the first test is significant at the 5% significance
level, then test the two-sided hypothesis that there is
a difference between CP52 and CP12 weight loss at
the 5% significance level.
Sample size calculation
We based the power calculation on data from our pre-
vious trials [8,9] with an expected difference of 2.3 kg
between BI and combined CP, 1.3 kg difference between
CP12 and CP52 (for example, a weight loss of 1.05 kg in
the BI arm, 2.7 kg in the CP12 arm and 4.0 kg in the
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CP52 arm), and an assumed standard deviation of 6 kg.
The statistical testing will be performed sequentially
firstly by comparing CP arms with BI and then only if
significant to then test for a difference between CP12
and CP52. Power is optimised by allocating more parti-
cipants to the CP arms where the smaller difference is
expected. With a sample of 1200 participants allocated
as 200 BI, 500 CP12 and 500 CP52, we will have 99.95%
power for the first test, to detect a difference of 2.3 kg
between BI and combined CP and 92.87% power to
detect a difference of 1.3 kg between CP12 and CP52.
The total power of the study will be 92.82%.
Clinical effectiveness
The primary analyses will assess differences in mean
weight change from baseline to 12 months between the
intervention groups. In order to investigate the impact of
missing data, four analysis approaches will be taken: com-
pleters only, baseline observation carried forward (BOCF),
last observation carried forward (LOCF) and a missing at
random (MAR) analysis using a variance components
model. For the LOCF, BOCF and completers analyses,
fixed effect models for continuous normal data will be
fitted to the 12 month weight data. The fixed effects will
be intervention group, centre and baseline weight. For the
MAR analysis, a model for multivariate normal data with
the same fixed effects will be fitted using measured
weights at each time point using generalised least squares.
Coefficient estimates and their 95% confidence intervals
will be calculated for each fixed effect.
All assumptions of the models will be checked using
appropriate graphs (eq a Q-Q plot of residuals to check
normality, residuals versus predicted values to check
homogeneity of residual variance.) If the residuals are not
normally distributed then the dependent variable may be
transformed to normality, if there is no such transfor-
mation then non-parametric methods will be considered.
Secondary analyses will include analyses of weight
change at 3 and 24 months; changes in blood pressure,
waist circumference and fat mass at 3, 12 and 24 months;
changes in biochemical measures at 12 months. These
will be analysed using the same regression based models.
Numbers of participants in each group achieving ≥5%
and ≥10% weight loss at 12 and 24 months will also be
explored.
Summary tables will be produced to look at the demo-
graphic distribution of the sample (age, sex, initial weight,
BMI); attendance rates; time course of attendance; website
usage.
Cost effectiveness
Within-trial cost-effectiveness
The incremental cost-effectiveness ratio of the intervention
is the main outcome of the economic evaluation and will
be expressed as incremental costs per incremental change
in weight/BMI for the within-trial evaluation. Cost items to
be included will be the cost of the intervention (i.e. cost to
NHS of referral packages and infrastructure related to the
operation of the referral scheme), primary, secondary, and
tertiary health care use associated with weight-related
disease (especially diabetes, coronary heart disease, colon
cancer, and musculo-skeletal disorders). At baseline, partici-
pants will complete a health care usage questionnaire co-
vering health service attendances and any weight loss
treatment for the previous 3 months. This questionnaire
will be completed again at 3, 12 and 24 months. Analysis of
uncertainty will be conducted with a non- parametric boot-
strap of the sampled data to generate a cost-effectiveness
acceptability curve showing the probability that the inter-
vention is cost-effective at various willingness-to-pay
thresholds per unit of outcome. The within-trial cost-
effectiveness analysis will be conducted jointly with the
outcome analysis in year 3 of the study. The data will also
be incorporated into the economic model.
Long term cost-effectiveness
Measuring cost-effectiveness in terms of costs per QALYs
will allow the intervention to be compared with many alter-
native uses of existing NHS budgets. We will use the UK
Health Forum’s “Obesity Micro-simulation Model”. The es-
timates the future burden of diseases by making evidence
based extrapolations of selected risk factors specific to the
following BMI related diseases; currently hypertension and
stroke, diabetes mellitus type 2, cardiovascular diseases in-
cluding angina pectoris, myocardial infarction, musculo-
skeletal disorders including osteoarthritis, low back pain
and knee arthrosis; obesity associated cancers including
colorectal, endometrial, ovarian, breast, cervical, prostate
and possibly also gallbladder, pancreatic and renal. The
micro-simulation incorporates a sophisticated economic
module. The module employs Markov-type simulation of
long-term health benefits, health care costs and cost-
effectiveness of specified interventions. It synthesises and
estimates evidence on cost-effectiveness analysis and cost-
utility analysis within the countries. The model is used to
project the differences in quality adjusted life years
(QALYs), lifetime health-care costs and as a consequence of
interventions incremental cost effectiveness ratios (ICERs).
Sensitivity analysis is also done within this model. Outputs
can be discounted for any specific discount rate.
Qualitative analysis
Audio recordings will be transcribed verbatim by an
external agency, checked for accuracy and imported into
NVivo, along with the original audio files. Basic descrip-
tive variables will be imported from the main trial data-
base to analyse the interview and diary data. Initial
analysis using a limited set of codes drawn directly from
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questions used in the topic guide will be conducted by
at least two members of the team to ensure general reli-
ability and appropriateness of categories. Analysis will
then proceed iteratively in order to remain sensitive to
the richness of data itself and develop a detailed hier-
archy of emerging themes that address more implicit,
and cross-cutting issues that emerge through the open-
nature of the interviews. Exploiting the dynamic capacity
of NVivo software, these themes will serve as the basis
for comparison between participants. Analysis of the
overall dataset will consequently enable both a narrative-
based account of individual experiences, but also the
extent to which they are intervention specific.
Discussion
With one quarter of adults defined as clinically obese,
and with growing financial pressures on health services,
this trial will provide important information on the use
of commercial providers to deliver weight management
services in partnership with health professionals. Find-
ings will provide transparent information about treat-
ment and outcomes and will enable formation of clear
guidance for commissioners and referring practitioners.
Guidance for commissioners from the Department of
Health in England currently recommends 12 week inter-
ventions. While there is some evidence that longer inter-
ventions might improve weight loss, this evidence is
inconsistent and generally comes from indirect compari-
sons between studies. Changing current practice to in-
clude longer referrals would require evidence of both
greater clinical effectiveness and cost-effectiveness at a
population level.
While the quantitative data in this study can provide
guidance on the clinical and cost-effectiveness of the
treatment, qualitative data will elucidate some key issues
surrounding commercial partnerships, in particular pa-
tient perceptions regarding the acceptability of these
interventions. This data will also provide insight into
what participants perceive are the active ingredients of
these interventions and what patients want weight ma-
nagement services to provide.
Data on psychosocial factors can be used to identify
inter-individual differences in weight trajectories and
could potentially be used to assist in stratifying patients
to treatments likely to be effective. Data on changes in
these factors during and following the intervention, and
their association with weight trajectories, could poten-
tially be used to inform improvements in existing inter-
ventions and the development of new interventions.
This trial endeavours to evaluate how effective this
intervention would be in routine clinical practice, rather
than under optimal controlled conditions. However, the
conditions of this trial differ somewhat from those of
routine clinical practice. Firstly, participants are recruited
by letter and all participants who meet inclusion criteria
and are invited. Thus our sample may be more
heterogenous than those who a GP refers following a
face-to-face consultation. Secondly, in two of the
research centres, participants attend a research centre for
their initial intervention allocation and all assessments.
This enables greater control over data quality and partici-
pant follow-up, but differs from how the intervention
would be rolled out in primary care.
Weight loss studies are notorious for high attrition,
which can compromise the analysis and interpretation of
data. While every effort will be made to enable partici-
pants to attend follow up assessments, continued partici-
pation in the trial is voluntary and we anticipate that
there will be a substantial number of people who do not
complete all measurements. However, this also reflects
what would happen in clinical practice where many
participants will not follow the programme they are
referred to, or may not return for follow-up. Data will be
analysed on an intention to treat basis. While no method
of analysis is without limitations, this should give the
best estimation of population level effectiveness.
Research governance
Ethical approval
This is version 2.9 of the trial protocol dated 28th July 2013.
The Medical Research Council is the sponsor of the trial.
This trial was registered at current controlled trials
ISRCTN85485463 on 12th October 2012. Ethical approval
was received from NRES Committee East of England -
Cambridge East (12/EE/0363) and local approvals from
NRES Committee North West - Liverpool Central
(12/NW/0678) and NRES Committee South Central –
Oxford 12/SC/0508. Local NHS Research and Develop-
ment approvals were received for all participating
practices.
Study sponsor
The Medical Research Council (MRC) will carry out the
role of sponsor, with MRC Human Nutrition Research
(HNR) the lead unit, in accordance with the Research
Governance Framework and will take on responsibility for
securing the arrangements to initiate, manage and finance
(subject to funding) the study, and to ensure any risks are
identified and managed and that the research is of high
quality. MRC HNR has been certified since January 2006 to
the quality management standard ISO9001:2008 by Lloyds
Register QA and is subject to twice yearly external audit.
Trial steering committee
The Trial Steering Committee (TSC) is chaired by Prof
Martin Roland, Professor of Health Services Research in
the University of Cambridge. Martin is Director of the
National Primary Care Research and Development centre,
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Special Advisor to RAND Europe and has been a practising
GP for over 30 years. Other independent members include:
Prof Nick Finer, who is Honorary Professor at UCL and
Consultant Endocrinologist at University College London
Hospitals and one of the leading UK specialists in obesity
management who has been a co-author in numerous
obesity-related trials; Dr Judith Dawson, a full-time GP and
Locality Lead for GP Commissioning in Northampton; and
two patient/public representatives, Mrs Norma Scullion
and Mr Graham Rhodes. Ms Polly Page, Director of Opera-
tions for MRC HNR and chair of the unit Research Review
Board is also a member of the TSC.
The study is not blinded and carries low risk with no
rules for early termination, so it is felt that it is neither
necessary nor appropriate to have a specific Data Moni-
toring and Ethics Committee in addition to the TSC.
Data handling and quality assurance
Participation will be under full informed consent, including
for the storage and use of data collected. The Principal
Investigator (PI) will be responsible for ensuring compli-
ance with the Data Protection Act. Data collection forms
will be kept in locked cabinets and an online database with
secure encrypted transmission will be established by the
database manager, accessible remotely by designated user-
names and passwords and automatically backed up to
ensure no loss of data. The PI and Trial Coordinator will
monitor the accuracy of the database with validation checks
against the data collection forms. All resulting datasets will
be anonymised and stored securely.
Research dissemination and data preservation for sharing
The investigators will analyse data according to pre-defined
analysis plans in a timely manner. For those analyses de-
scribed in this proposal this will be within the lifetime of
the grant. The PI shall ensure that the results of the trial
will be submitted for publication in a peer reviewed journal,
regardless of the outcome. Authorship of publications will
be determined by ICMJE guidelines. As project partners,
Weight Watchers understand that they will have no influ-
ence on the data analyses or publications, but they will be
able to see publications 14 days prior to submission to
check any factual information relating to the company. All
scientific papers and reports are peer reviewed by the HNR
Research Review Board and signed off before publication.
A lay summary of the research findings will also be sent to
participants and participating primary care practices at the
end of the study.
MRC HNR will be custodians of the data resulting
from the study and will ensure compliance with the Data
Protection Act and the MRC policy for data sharing and
preservation. The HNR database manager will take
responsibility for data curation and archiving and all
data sets will be kept securely with no access from
unauthorised personnel. Data will be stored so that it
can be accessed, used and understood by subsequent
users. When the investigators have completed their
planned analyses, the anonymised data will be made
available for use by others and will be shared under
appropriate data sharing agreements. Primary data and
the Trial Master File will be retained securely in their
original form for a minimum of 10 years.
The commercial programme intervention will be deli-
vered by an employee of company and the company will
provide data on meeting attendance and website usage,
but they will have no role in the study design, data
analysis, data interpretation, or writing of the report.
Trial status
Ongoing. Recruitment was completed in February 2014.
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